“Michael has been an advocate and supporter of my career as a leader and entrepreneur. I sought his advice and guidance on multiple fields that concerned business operations. I am grateful to him for recognizing high potential opportunities that could make a difference in society. His exemplary career as a corporate leader and investor, taking risks while providing support along the way has earned him many long lasting relationships in the industry. ”
Activity
-
Why did Novo Nordisk choose Vault CRM?
Why did Novo Nordisk choose Vault CRM?
Liked by Michael Cloutier
-
Developed in partnership with Patrick Lencioni, The Five Behaviors is an out of the box, all-in-one classroom solution that helps your clients…
Developed in partnership with Patrick Lencioni, The Five Behaviors is an out of the box, all-in-one classroom solution that helps your clients…
Liked by Michael Cloutier
-
Started the day with powerful women! Thank you to Rashel Hariri of She's Interesting and Alex Behal of Inovia Capital for hosting!! And Manon…
Started the day with powerful women! Thank you to Rashel Hariri of She's Interesting and Alex Behal of Inovia Capital for hosting!! And Manon…
Liked by Michael Cloutier
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Licenses & Certifications
-
Strategic Management
Wharton Business School
Recommendations received
5 people have recommended Michael
Join now to viewMore activity by Michael
-
Excited to be at the #WomensSummit in beautiful Ottawa today with Kristina Ireland, MBA, PMP celebrating, collaborating and learning with a large…
Excited to be at the #WomensSummit in beautiful Ottawa today with Kristina Ireland, MBA, PMP celebrating, collaborating and learning with a large…
Liked by Michael Cloutier
-
Zeal and passion for patients is what its all about!! Share and be proud of your success. Nows the time!! #leadership
Zeal and passion for patients is what its all about!! Share and be proud of your success. Nows the time!! #leadership
Shared by Michael Cloutier
-
Love your thinking Chris!! #patientsfirst #leadership
Love your thinking Chris!! #patientsfirst #leadership
Shared by Michael Cloutier
Other similar profiles
Explore more posts
-
Dr. Timos Papagatsias
Thoughts on this? >> CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B - Canada NewsWire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #competitivemarketing
-
Accelsiors CRO
British Columbia's Biosimilars Initiative has successfully saved about $732 million over five years by transitioning over 40,000 patients from reference biologics to biosimilars, without compromising health outcomes. This incredible achievement was not merely due to changing prescriptions, but thanks to a comprehensive program for patients and physicians. Key aspects of the initiative included: 🔄 6-month transition period 📜 A requirement for a new prescription from a prescriber for the switch 💬 Support fees for prescribers and pharmacists assisting patients 📝 Patient lists for prescribers 🔍 Consultations with patient groups, clinicians, professional bodies, insurers, and drug sponsors 📚 Educational and support tools for patients and healthcare providers 📢 Coordinated communications 📊 Monitoring biosimilar utilization ❗Exceptional coverage for patients unable to switch for clinical reasons ⛔ Delisting reference biologics after the transition period With adoption rates of 91%-95% within 24 months, BC's model exemplifies effective biosimilar adoption for cost savings and improved patient care, setting a precedent for other regions. Explore how we integrate patient insights into clinical trials and healthcare solutions: >> https://lnkd.in/dtgXSjVm >> https://lnkd.in/dc4kXmjw #biosimilars #patients #clinicalresearch #clinicaltrials #healthcare #biotech
1 Comment -
Korro Bio, Inc.
Korro will be participating in the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, which will take place in Montreal from October 6-9. Venkat Krishnamurthy, Ph.D., our Senior Vice President, Head of Platform, will deliver a presentation on KRRO-110, targeting alpha-1 antitrypsin deficiency (#AATD). Oral Presentation Details: Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) When: Monday, October 7, 3:20 PM ET We’re also proud to share two poster presentations by our scientists: Agya Karki, Ph.D. will present on the purification of human ADAR for evaluating oligo-directed RNA editing (Poster #P133). Zhiji Ren, Ph.D. will discuss on-target and off-target behaviors of RNA editing oligonucleotides using ADAR1 chimeric eCLIP (Poster #P228). Learn more: https://lnkd.in/ef2FRJaX #OTS2024 #OligoMeeting #OligoTherapeutics #Oligonucleotide #RNAEditing
3 Comments -
Biocon Biologics
The Canadian healthcare system and regulatory framework are unique. Rosemarie Childerhose, Head, Market Access & Pricing, Canada, explains how Biocon Biologics team is making biosimilars available to patients in Canada. [https://lnkd.in/gTC-z3wc ] #BioconBiologics #MarketAccess #Canada
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Michael Cloutier in Canada
49 others named Michael Cloutier in Canada are on LinkedIn
See others named Michael Cloutier